PureTech Health (LON:PRTC) Shares Down 9.2% – Time to Sell?

Shares of PureTech Health plc (LON:PRTC) were down 9.2% during mid-day trading on Tuesday . The stock traded as low as GBX 126 and last traded at GBX 126. Approximately 1,066,844 shares were traded during trading, a decline of 15% from the average daily volume of 1,249,921 shares. The stock had previously closed at GBX 138.80.

PureTech Health Stock Performance

The firm has a fifty day moving average of GBX 121.85 and a 200-day moving average of GBX 125.88. The stock has a market capitalization of £306.71 million, a price-to-earnings ratio of -2.74 and a beta of 1.35. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.